Absorbable Hemostat Sales

Absorbable Hemostat Sales Market Outlook

The global absorbable hemostat sales market is projected to reach approximately USD 2.5 billion by 2035, with a robust compound annual growth rate (CAGR) of around 6.5% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing demand for minimally invasive surgical procedures, coupled with the rising prevalence of chronic diseases that require surgical intervention. Moreover, advancements in surgical techniques and the growing awareness regarding effective wound management methods are further propelling the demand for absorbable hemostats across various medical fields. Additionally, the expansion of healthcare infrastructure and the increasing number of surgical procedures in emerging economies are also expected to contribute significantly to market growth.

Growth Factor of the Market

A variety of factors are driving the growth of the absorbable hemostat sales market, particularly the increasing incidence of traumatic injuries and surgical procedures worldwide. As the healthcare sector continues to evolve with innovative technologies, the emphasis on patient safety and effective bleeding control has become paramount. The growing preference for absorbable hemostats over traditional methods is also a significant growth factor since they minimize the risk of complications and promote faster healing. Furthermore, the rising geriatric population, who are more susceptible to surgical interventions, is anticipated to bolster demand. The presence of advanced healthcare facilities and the continuous research and development initiatives undertaken by key players in the market play a critical role in enhancing product offerings, thereby stimulating market growth.

Key Highlights of the Market

• The absorbable hemostat market is projected to grow at a CAGR of 6.5% from 2025 to 2035.
• North America currently holds the largest market share, driven by advanced healthcare infrastructure and high surgical volumes.
• Collagen-based hemostats are the most widely used product type due to their effectiveness and biocompatibility.
• The orthopedic surgery segment is expected to witness significant growth due to the rising incidence of sports injuries and orthopedic conditions.
• Online sales channels are gaining traction, offering convenience and a broader reach to both consumers and healthcare providers.

By Product Type

Collagen-based Hemostats:

Collagen-based hemostats are widely recognized for their efficacy in promoting hemostasis during surgical procedures. These products leverage the natural properties of collagen to enhance the coagulation process, making them an ideal choice for various surgical applications. Their biocompatibility ensures minimal adverse reactions, which is crucial in surgeries involving soft tissues. The increasing preference for collagen-based solutions is driven by their ability to integrate seamlessly with bodily tissues, leading to improved healing outcomes. As a result, this product type is projected to dominate the market, supported by ongoing research and product innovations aimed at enhancing their performance.

Gelatin-based Hemostats:

Gelatin-based hemostats are made from porcine or bovine gelatin and are known for their rapid absorption characteristics. These products are effective in controlling mild to moderate bleeding in surgical settings, offering a reliable solution for surgeons. The ease of application and rapid hemostatic action make gelatin-based hemostats particularly popular in cardiac and orthopedic surgeries. Additionally, the growing trend toward minimally invasive surgical techniques has further bolstered the demand for these hemostats, as they can be easily applied in difficult-to-reach areas. Their versatility and effectiveness continue to contribute to their increasing market share, making them a preferred choice for many surgical applications.

Oxidized Regenerated Cellulose-based Hemostats:

Oxidized regenerated cellulose-based hemostats have gained prominence due to their unique properties that facilitate effective bleeding control and tissue healing. These products are biodegradable and provide a mechanical barrier that aids in hemostasis while supporting tissue regeneration. Their effectiveness in both major and minor surgeries has broadened their application scope, making them suitable for diverse surgical fields, from general to cardiac surgery. The growing emphasis on biocompatibility and the minimal risk of foreign body reactions further enhance their appeal among healthcare professionals. As awareness about these advantages continues to spread, the market for oxidized regenerated cellulose-based hemostats is expected to experience substantial growth.

Combination Hemostats:

Combination hemostats are engineered to incorporate multiple active ingredients, thereby offering a synergistic effect in promoting hemostasis. These products are designed to address various bleeding challenges across different surgical settings more effectively. The versatility of combination hemostats allows them to cater to a wide range of surgical procedures, increasing their adoption in hospitals and surgical centers. Additionally, their ability to provide rapid and effective bleeding control further enhances their value proposition. The trend towards customized solutions in the healthcare industry is likely to drive the growth of combination hemostats, as practitioners seek products that can adapt to specific surgical scenarios.

Thrombin-based Hemostats:

Thrombin-based hemostats are derived from human or animal sources and are known for their potent hemostatic properties. By mimicking the natural coagulation process, these products facilitate rapid clot formation, making them highly effective in various surgical applications. Thrombin-based hemostats are particularly beneficial in cases of severe bleeding, where traditional methods may fall short. Their extensive use in cardiac and neurosurgery underscores their importance in critical surgical scenarios. Despite the advantages, the market for thrombin-based hemostats is subject to stringent regulatory scrutiny, necessitating continuous innovation and adherence to safety standards to maintain market viability.

By Application

Orthopedic Surgery:

Orthopedic surgery is one of the primary applications for absorbable hemostats due to the high incidence of trauma-related injuries and surgical interventions in this field. The ability of hemostats to control bleeding effectively is crucial in orthopedic procedures, where precision and rapid recovery are paramount. The increasing participation in sports and rising prevalence of musculoskeletal disorders are contributing to a greater demand for orthopedic surgeries, thus fueling the use of hemostatic agents. As advancements in surgical techniques continue to evolve, the reliance on absorbable hemostats to minimize complications and ensure effective healing remains strong, leading to a significant market share in this segment.

General Surgery:

General surgery encompasses a broad range of procedures, making it a vital segment for absorbable hemostats. These products are utilized to manage bleeding during surgeries involving various organs and tissues. The versatility of hemostatic agents makes them suitable for both minor and major procedures, enhancing their market presence. As surgical techniques evolve, the demand for effective hemostatic solutions has increased, driving the adoption of absorbable hemostats in general surgery. The growing focus on patient safety and optimal surgical outcomes emphasizes the importance of hemostatic agents in reducing complications and enabling quicker recoveries.

Cardiac Surgery:

Cardiac surgery represents a critical area of application for absorbable hemostats due to the complex nature of procedures and the significant risk of bleeding. The ability of these hemostats to achieve rapid hemostasis is essential in managing the delicate tissues involved in cardiac surgeries. With advancements in minimally invasive techniques, the use of absorbable hemostats has become more prevalent, as they provide effective bleeding control without the need for additional sutures. The rising incidence of cardiovascular diseases has resulted in an increased number of surgeries, further propelling the demand for hemostatic agents in this segment of the market.

Cosmetic Surgery:

Cosmetic surgery has seen a surge in popularity over the years, leading to an increased demand for absorbable hemostats in aesthetic procedures. These products are utilized to manage bleeding during surgeries such as facelifts, breast augmentations, and liposuction, where precision is essential. The use of absorbable hemostats in cosmetic surgery not only aids in controlling bleeding but also promotes optimal healing, which is crucial for aesthetic outcomes. As the focus on minimally invasive procedures continues to rise, the demand for effective hemostatic solutions in cosmetic surgery is expected to grow, providing opportunities for manufacturers to innovate and cater to this expanding market.

Neurosurgery:

Neurosurgery is a highly specialized field that requires meticulous surgical techniques and effective bleeding control. Absorbable hemostats play a vital role in managing bleeding during complex brain and spinal surgeries, where traditional methods may not be sufficient. The unique properties of hemostatic agents allow for rapid clot formation while minimizing tissue damage, which is critical in neurosurgical procedures. As advancements in neurosurgery continue to progress, the reliance on absorbable hemostats to ensure patient safety and successful outcomes is anticipated to increase, further solidifying their position in this crucial application segment.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for absorbable hemostats, given the high volume of surgical procedures performed in these facilities. Various surgical departments rely heavily on hemostatic agents to control bleeding during operations, making hospitals the largest consumers of these products. The comprehensive range of surgical specialties within hospitals creates an extensive demand for absorbable hemostats, thus driving their sales. Additionally, the establishment of supply contracts between manufacturers and hospitals ensures consistent availability and facilitates the procurement process, further enhancing the market for hemostatic agents in hospital settings.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) have emerged as a significant distribution channel for absorbable hemostats due to the growing trend of outpatient surgeries. These facilities conduct a wide range of procedures, from minor surgeries to complex operations, necessitating effective bleeding control solutions. The preference for outpatient settings stems from the advantages of reduced hospital stays and lower healthcare costs, prompting ASCs to adopt absorbable hemostats in their surgical practices. As the demand for outpatient procedures continues to rise, the role of ASCs as a distribution channel for hemostatic agents is expected to expand, creating new opportunities for manufacturers in the market.

Specialty Clinics:

Specialty clinics are another important distribution channel for absorbable hemostats, particularly in fields such as dermatology, cosmetic surgery, and orthopedics. These clinics often perform specialized procedures that require effective hemostatic solutions to manage bleeding. The increasing number of specialty clinics, paired with the growing demand for targeted surgical interventions, has contributed to the rising use of absorbable hemostats in these settings. Moreover, the personalized patient care approach in specialty clinics encourages the adoption of advanced medical technologies, including innovative hemostatic agents, further stimulating market growth within this distribution channel.

Online Sales:

The rise of e-commerce has transformed the distribution landscape for absorbable hemostats, with online sales channels gaining significant traction. Healthcare providers and facilities are increasingly turning to online platforms for their medical supply needs, seeking the convenience and broader access offered by digital channels. Online sales allow for competitive pricing and streamlined ordering processes, making it easier for healthcare professionals to procure essential products. As the trend towards digitalization continues, the online sales channel is expected to play a crucial role in the distribution of absorbable hemostats, offering opportunities for manufacturers to reach a wider audience and enhance their market presence.

By Ingredient Type

Plant-based Hemostats:

Plant-based hemostats have gained attention due to the increasing demand for natural and sustainable medical products. These hemostats utilize natural plant-derived materials that exhibit hemostatic properties, making them a preferred choice for environmentally-conscious consumers and healthcare providers. The effectiveness of plant-based hemostats in controlling bleeding while promoting tissue healing aligns with the growing trend toward biocompatibility and reduced side effects. As regulatory bodies encourage the use of safe and natural ingredients in medical products, the market for plant-based hemostats is anticipated to witness significant growth in the coming years.

Animal-based Hemostats:

Animal-based hemostats, derived from sources such as porcine or bovine products, have long been a staple in surgical settings due to their proven effectiveness in promoting clot formation. These hemostatic agents are particularly popular in various surgical applications, offering reliable performance in managing bleeding. Despite the effectiveness, there is an increasing scrutiny regarding the source of animal products and potential allergic reactions, which may affect market perceptions. However, ongoing research and development efforts aim to enhance the safety and efficacy of animal-based hemostats, ensuring their relevance in the rapidly evolving healthcare landscape.

Synthetic Hemostats:

Synthetic hemostats present a synthetic alternative to traditional hemostatic agents, offering controlled properties and predictable performance. These products are engineered to facilitate rapid clot formation while minimizing the risk of adverse reactions, making them suitable for a wide range of surgical applications. The growing demand for innovative surgical solutions has propelled the development of synthetic hemostats, as they provide customizable options to meet specific clinical needs. As advancements in materials science continue to unfold, synthetic hemostats are expected to gain market share, driven by their versatility and adaptability in various surgical contexts.

Combination Hemostats:

Combination hemostats, which incorporate multiple active ingredients, have garnered attention for their enhanced hemostatic properties. By leveraging the strengths of various components, these products can address different bleeding challenges more effectively. The versatility of combination hemostats allows them to cater to diverse applications, making them popular among healthcare professionals. Their ability to offer rapid and effective bleeding control enables quicker recovery times, which is a crucial factor in surgical success. As the focus on personalized medicine and tailored solutions grows, the demand for combination hemostats is expected to rise, further solidifying their position in the market.

By Region

The North American region currently dominates the absorbable hemostat sales market, accounting for a significant share of the overall market. Factors such as advanced healthcare infrastructure, high surgical volumes, and a strong focus on innovation in medical technologies contribute to this dominance. The increasing prevalence of chronic diseases and rising awareness regarding effective wound management also amplify the demand for absorbable hemostats in this region. Moreover, the growing geriatric population, who are more prone to surgical procedures, further propels market growth in North America, with a CAGR of approximately 6.8% projected over the forecast period.

In Europe, the absorbable hemostat sales market is also showing promising growth, driven by expanding healthcare facilities and increasing surgical procedures. The presence of key market players and ongoing research initiatives in the region are likely to enhance the development of innovative hemostatic solutions. The market is expected to grow at a CAGR of around 5.9%, fueled by the increasing adoption of minimally invasive surgeries and rising investments in healthcare technologies. Additionally, countries such as Germany, the UK, and France are anticipated to contribute significantly to market expansion, underscoring the region's importance in the global absorbable hemostat landscape.

Opportunities

The absorbable hemostat sales market presents numerous opportunities driven by several trends in the healthcare industry. One of the most significant opportunities lies in the increasing demand for minimally invasive surgical procedures, which are gaining popularity for their associated benefits, including reduced recovery times and lower complication rates. As surgeons seek effective solutions to manage bleeding during these procedures, absorbable hemostats are becoming essential tools. Additionally, as healthcare providers focus on improving patient outcomes and minimizing healthcare costs, the demand for effective and easy-to-use hemostatic solutions is projected to rise. This convergence of trends creates a fertile ground for companies to innovate and expand their product portfolios, enhancing their competitive advantage in the market.

Furthermore, the growing emphasis on research and development presents a substantial opportunity for market players to introduce novel absorbable hemostatic products. With advancements in materials science and biotechnology, there is significant potential for developing hemostats that offer improved efficacy, safety, and versatility. Collaborations between pharmaceutical companies, research institutions, and medical professionals can lead to groundbreaking innovations and new product formulations. Additionally, expanding into emerging markets where surgical procedures are on the rise can offer lucrative prospects for manufacturers. By strategically positioning themselves to meet the evolving needs of healthcare providers and patients, companies can capitalize on these opportunities for sustained growth and profitability in the absorbable hemostat sales market.

Threats

While the absorbable hemostat sales market is poised for growth, several threats can impede progress. The increasing competition from alternative hemostatic products poses a significant challenge, as manufacturers strive to differentiate their offerings in a crowded marketplace. The emergence of non-absorbable hemostatic agents, which may provide specific advantages in certain surgical scenarios, could divert attention from absorbable options. Furthermore, stringent regulatory requirements regarding the safety and efficacy of medical products may lead to delays in the approval process for new hemostatic solutions, hindering market entry for innovative products and slowing overall market growth.

Additionally, fluctuations in raw material prices and supply chain disruptions can affect production costs and availability, posing risks for manufacturers. The ongoing global health crises, such as the COVID-19 pandemic, have highlighted vulnerabilities within supply chains, impacting the timely distribution of medical products. Companies must navigate these potential disruptions while maintaining compliance with regulatory standards and fulfilling the needs of healthcare providers. As the market evolves, addressing these threats will be essential for sustaining competitiveness and ensuring the continued growth of the absorbable hemostat sales market.

Competitor Outlook

• Johnson & Johnson
• Medtronic
• Ethicon (a subsidiary of Johnson & Johnson)
• BSN Medical
• 3M Health Care
• Cardinal Health
• Integra LifeSciences Corporation
• Coloplast A/S
• Hemostasis, Inc.
• Z-Medica LLC
• Gelita Medical GmbH
• W.L. Gore & Associates, Inc.
• Sanofi S.A.
• Baxter International Inc.
• HemaClear LLC

The competitive landscape of the absorbable hemostat sales market is characterized by a mix of established players and emerging companies striving to capture market share through innovation and strategic partnerships. Major companies like Johnson & Johnson and Medtronic lead the market with extensive product portfolios and strong global presence. These companies benefit from substantial investments in research and development, allowing them to continuously introduce innovative hemostatic products that meet the evolving needs of healthcare providers. Additionally, strategic mergers and acquisitions enable these firms to expand their market reach and enhance their competitive positioning.

Emerging players and niche companies are also making their mark in the absorbable hemostat market by focusing on developing specialized products and targeting specific surgical applications. These companies leverage advancements in technology and materials science to create innovative solutions that offer unique benefits over traditional hemostatic agents. As the market continues to evolve, collaborative efforts between leading manufacturers and startups can drive further innovation, ultimately enhancing the range of options available to healthcare providers.

Furthermore, the trend toward personalized medicine and tailored solutions presents significant opportunities for companies that can adapt their offerings to meet the specific needs of different surgical specialties. The ability to leverage data analytics and customer insights can support the development of targeted marketing strategies and product enhancements that resonate with practitioners. As competition intensifies and market dynamics shift, companies that prioritize innovation, customer engagement, and strategic partnerships will be best positioned to thrive in the absorbable hemostat sales market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 BSN Medical
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Sanofi S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Z-Medica LLC
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Coloplast A/S
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 HemaClear LLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 3M Health Care
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Cardinal Health
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Hemostasis, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Johnson & Johnson
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gelita Medical GmbH
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Baxter International Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 W.L. Gore & Associates, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Integra LifeSciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Ethicon (a subsidiary of Johnson & Johnson)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Absorbable Hemostat Sales Market, By Application
    • 6.1.1 Orthopedic Surgery
    • 6.1.2 General Surgery
    • 6.1.3 Cardiac Surgery
    • 6.1.4 Cosmetic Surgery
    • 6.1.5 Neurosurgery
  • 6.2 Absorbable Hemostat Sales Market, By Product Type
    • 6.2.1 Collagen-based Hemostats
    • 6.2.2 Gelatin-based Hemostats
    • 6.2.3 Oxidized Regenerated Cellulose-based Hemostats
    • 6.2.4 Combination Hemostats
    • 6.2.5 Thrombin-based Hemostats
  • 6.3 Absorbable Hemostat Sales Market, By Ingredient Type
    • 6.3.1 Plant-based Hemostats
    • 6.3.2 Animal-based Hemostats
    • 6.3.3 Synthetic Hemostats
    • 6.3.4 Combination Hemostats
    • 6.3.5 Hemostatic Agents
  • 6.4 Absorbable Hemostat Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Absorbable Hemostat Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Absorbable Hemostat Sales market is categorized based on

By Product Type

• Collagen-based Hemostats
• Gelatin-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Thrombin-based Hemostats

By Application

• Orthopedic Surgery
• General Surgery
• Cardiac Surgery
• Cosmetic Surgery
• Neurosurgery

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Online Sales

By Ingredient Type

• Plant-based Hemostats
• Animal-based Hemostats
• Synthetic Hemostats
• Combination Hemostats
• Hemostatic Agents

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Johnson & Johnson
• Medtronic
• Ethicon (a subsidiary of Johnson & Johnson)
• BSN Medical
• 3M Health Care
• Cardinal Health
• Integra LifeSciences Corporation
• Coloplast A/S
• Hemostasis, Inc.
• Z-Medica LLC
• Gelita Medical GmbH
• W.L. Gore & Associates, Inc.
• Sanofi S.A.
• Baxter International Inc.
• HemaClear LLC